Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer

Colorectal cancer (CRC) patients with metastatic lesions have low 5-year survival rates. During metastasis, cancer cells often obtain unique characteristics such as epithelial–mesenchymal transition (EMT). Vimentin a biomarker contributes to EMT by changing cell shape and motility. Since abnormal ph...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2020-06, Vol.69 (6), p.989-999
Hauptverfasser:	Ohara, Mizuho, Ohara, Kenzo, Kumai, Takumi, Ohkuri, Takayuki, Nagato, Toshihiro, Hirata-Nozaki, Yui, Kosaka, Akemi, Nagata, Marino, Hayashi, Ryusuke, Harabuchi, Shohei, Yajima, Yuki, Oikawa, Kensuke, Harabuchi, Yasuaki, Sumi, Yasuo, Furukawa, Hiroyuki, Kobayashi, Hiroya
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antigens Cancer Cancer Research CD4 antigen CD8 antigen Cell Line Cell Line, Tumor Cell size Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Cytotoxicity Epitopes Female Humans Immunology Immunotherapy Immunotherapy - methods Lymphocytes Lymphocytes T Male Malignancy Medicine Medicine & Public Health Mesenchyme Metastases Metastasis Middle Aged Neoplasm Metastasis Oncology Original Original Article Phosphorylation Post-translation Tumor cells Vimentin Vimentin - pharmacology Vimentin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!